The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.50
Bid: 15.00
Ask: 16.00
Change: -2.50 (-13.89%)
Spread: 1.00 (6.667%)
Open: 15.50
High: 16.50
Low: 15.50
Prev. Close: 18.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

2 Mar 2011 16:54

RNS Number : 2250C
Angle PLC
02 March 2011
 



ANGLE plc ("the Company")

 

Director's share transfer

 

ANGLE plc ("ANGLE"), the international venture management company focusing on the commercialisation of technology and the development of technology-based industry, announces that it has received notification from Andrew Newland, Chief Executive of ANGLE, regarding the transfer of ordinary shares of 10p each ("Ordinary Shares") in the Company.

 

The Company was notified on 2 March 2011 that on the same day Andrew Newland transferred off market 544,690 ordinary shares of 10 pence each in the Company ("Ordinary Shares") to his personal pension fund at a price of 27.5 pence per share; 509,898 Ordinary Shares were transferred from himself and 34,792 Ordinary Shares from his wife, Mrs Harriet Newland.

 

There is no change to Mr Newland's beneficial interest in the Company, which following this notification remains at 7,054,686 Ordinary Shares representing 23.18 per cent. of the Company's issued share capital.

 

 

For further information:

 

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Collins Stewart Europe Limited

Stewart Wallace

 

0207 523 8350

Scott Harris

Stephen Scott, James O'Shaughnessy, Harry Dee

 

0207 653 0030

 

Notes to Editors

 

ANGLE plc

 

Founded in 1994, ANGLE focuses on the commercialisation of technology and the development of technology-based industry. ANGLE creates, develops and advises technology businesses on its own behalf and for its clients.

 

ANGLE's specialist Management services business provides support on a fee-for-service basis to major clients around the world involved in incubation, IP commercialisation, SME innovation and growth and the operation of science & technology parks.

 

ANGLE also owns a portfolio of company holdings with high growth potential in the medical and technology sectors. These have been developed whilst subsidiaries of ANGLE using its proprietary Progeny® process. ANGLE seeks to retain a substantial shareholding in these companies with a view to ongoing returns from dividend, milestone, royalty and capital returns.

 

ANGLE's technology commercialisation skills are of increasing relevance as global economies focus on regeneration, innovation and value added components to their industries. ANGLE's technology skills in IT and software, medical and life sciences, cleantech and renewable energies are directly relevant to major growth markets of the future and are marketed as specialised Management services.

 

ANGLE is quoted on AIM (AGL.L); further information can be found on www.ANGLEplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSQLLFBFXFEBBX
Date   Source Headline
24th Mar 20147:00 amRNSAppointment of Scientific Adviser
17th Mar 20147:00 amRNSParsortix FDA Submission
24th Feb 20147:00 amRNSUse of Parsortix System with Liver Cancer Patients
18th Feb 20147:00 amRNSParsortix Launch at Circulate Conference in Berlin
30th Jan 20147:00 amRNSInterim Results
13th Jan 20147:00 amRNSCambridge Parsortix Laboratory
10th Jan 20147:00 amRNSNotification of Interim Results and Webcast
7th Jan 20147:00 amRNSAppointment of Scientific Adviser
17th Dec 20137:00 amRNSCE Mark Authorisation
13th Dec 20137:00 amRNSRaises £6.2m from Sale of Geomerics
31st Oct 20133:31 pmRNSResult of 2013 Annual General Meeting
9th Oct 20137:00 amRNSAnnual Report and Accounts and Notice of AGM
31st Jul 20137:00 amRNSPreliminary Results
25th Jul 20137:00 amRNSPositive Evaluation of Parsortix System
19th Jul 20137:00 amRNSNotification of Preliminary Results and Webcast
8th Jul 20137:00 amRNSParsortix Colorectal Cancer Validation
29th May 20137:00 amRNSDirector's Share Transfer
28th May 20137:00 amRNSParsortix Manufacturer Appointed
13th May 20137:00 amRNSPARSORTIX CELL HARVESTING
7th May 20137:00 amRNSParsortix Regulatory Approval Update
28th Feb 20137:00 amRNSParsortix Research Product Launch
15th Feb 201310:56 amRNSDirector's share transfer
31st Jan 20137:01 amRNSFundraising and Director's Dealings
31st Jan 20137:00 amRNSInterim Results
16th Jan 20137:00 amRNSNotification of Interim Results and Webcast
14th Jan 20137:00 amRNSParsortix Cell Recovery
7th Jan 20137:00 amRNSAppointment of NED
18th Dec 20127:00 amRNSParsortix Released to Research Partners
10th Dec 20127:00 amRNSBUSINESS UPDATE
18th Oct 20127:00 amRNSAppointment of Scientific Advisers
17th Oct 20123:45 pmRNSHolding(s) in the Company
11th Oct 20123:39 pmRNSResult of 2012 Annual General Meeting
3rd Sep 20127:00 amRNSIncreased Fundraising
1st Aug 20127:00 amRNSIncreased Fundraising
26th Jul 20127:01 amRNSFundraising
26th Jul 20127:00 amRNSPreliminary Results
24th Jul 20127:00 amRNSNotice of Preliminary Results and Conference Call
27th Jun 20127:00 amRNSOffer Unconditional for Novocellus' Partner Origio
7th Jun 20127:00 amRNSUpdate Re Novocellus' Partner ORIGIO A/S
16th May 20127:00 amRNSGeomerics Milestone Payment
30th Apr 20127:00 amRNSParsortix Design Breakthrough
26th Apr 20127:00 amRNSLaunches New Corporate Website
23rd Apr 20127:00 amRNSParsortix Update for Breast Cancer
17th Apr 20127:00 amRNSParsortix Validation for Ovarian Cancer
11th Apr 20127:00 amRNSNovocellus Embryosure® Trial Started
26th Mar 20127:00 amRNSGeomerics Update
15th Mar 20127:00 amRNSParsortix Validation for Colon Cancer
7th Mar 20128:00 amRNSHolding(s) in the Company
28th Feb 201212:00 pmRNSDirector Share Transfer
28th Feb 20128:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.